Related Research Articles
Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.
Alcoholic liver disease (ALD), also called alcohol-related liver disease (ARLD), is a term that encompasses the liver manifestations of alcohol overconsumption, including fatty liver, alcoholic hepatitis, and chronic hepatitis with liver fibrosis or cirrhosis.
Liver transplantation or hepatic transplantation is the replacement of a diseased liver with the healthy liver from another person (allograft). Liver transplantation is a treatment option for end-stage liver disease and acute liver failure, although availability of donor organs is a major limitation. The most common technique is orthotopic transplantation, in which the native liver is removed and replaced by the donor organ in the same anatomic position as the original liver. The surgical procedure is complex, requiring careful harvest of the donor organ and meticulous implantation into the recipient. Liver transplantation is highly regulated, and only performed at designated transplant medical centers by highly trained transplant physicians and supporting medical team. Favorable outcomes require careful screening for eligible recipients, as well as a well-calibrated live or deceased donor match.
Autoimmune hepatitis, formerly known as lupoid hepatitis, plasma cell hepatitis, or autoimmune chronic active hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells, causing the liver to be inflamed. Common initial symptoms may include fatigue, nausea, muscle aches, or weight loss or signs of acute liver inflammation including fever, jaundice, and right upper quadrant abdominal pain. Individuals with autoimmune hepatitis often have no initial symptoms and the disease may be detected by abnormal liver function tests and increased protein levels during routine bloodwork or the observation of an abnormal-looking liver during abdominal surgery.
Terminal illness or end-stage disease is a disease that cannot be cured or adequately treated and is expected to result in the death of the patient. This term is more commonly used for progressive diseases such as cancer, dementia or advanced heart disease than for injury. In popular use, it indicates a disease that will progress until death with near absolute certainty, regardless of treatment. A patient who has such an illness may be referred to as a terminal patient, terminally ill or simply as being terminal. There is no standardized life expectancy for a patient to be considered terminal, although it is generally months or less. Life expectancy for terminal patients is a rough estimate given by the physician based on previous data and does not always reflect true longevity. An illness which is lifelong but not fatal is a chronic condition.
Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder characterized by inflammation and scarring of the bile ducts, which normally allow bile to drain from the gallbladder. Affected individuals may have no symptoms or may experience signs and symptoms of liver disease, such as yellow discoloration of the skin and eyes, itching, and abdominal pain.
Acute liver failure is the appearance of severe complications rapidly after the first signs of liver disease, and indicates that the liver has sustained severe damage. The complications are hepatic encephalopathy and impaired protein synthesis. The 1993 classification defines hyperacute as within 1 week, acute as 8–28 days, and subacute as 4–12 weeks; both the speed with which the disease develops and the underlying cause strongly affect outcomes.
Roger Stanley Williams CBE FRCS FRCP FRCPE FRACP FMedSci was a British professor of hepatology. He was Director of the Institute of Hepatology, London and Professor of Hepatology, King's College London. He was also Medical Director of the charity, the Foundation for Liver Research a UK registered charity and was the lead person of the Lancet Commission into Liver Disease in the UK.
Southern Illinois University School of Medicine is a medical school located in Springfield, the capital of the U.S. state of Illinois. It is part of the Southern Illinois University system, which includes a campus in Edwardsville as well as the flagship in Carbondale. The medical school was founded in 1970 and achieved full accreditation in 1972. It was founded to relieve a chronic shortage of physicians in downstate Illinois.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the name adopted in 2023 for the condition previously known as non-alcoholic fatty liver disease (NAFLD). This condition is diagnosed when there is excessive fat build-up in the liver, and at least one metabolic risk factor. When there is also moderate alcohol use, the term MetALD is used, and these are differentiated from alcoholic liver disease (ALD) when this is the sole cause of steatotic liver disease. The terms non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis have been used to describe different severities, the latter indicating the presence of further liver inflammation. NAFL is less dangerous than NASH and usually does not progress to it, but this progression may eventually lead to complications, such as cirrhosis, liver cancer, liver failure, and cardiovascular disease.
The King's College Criteria or the King's College Hospital criteria were devised in 1989 to determine if there were any early indices of poor prognosis in patients with acute liver failure. Acute liver failure is defined as the onset of encephalopathy or coagulopathy within 26 weeks of a patient diagnosed with liver disease. Patients with hepatitis B acquired at birth, Wilson's disease and autoimmune hepatitis are included if their disease was identified within the past 26 weeks. These patients are very ill, and have a very high risk of dying of their illness without adequate treatment which may include liver transplantation. It is important that physicians find ways of identifying patients with acute liver failure early in their course who will do poorly, and may require liver transplantation. The King's College Criteria have consistently shown excellent operating characteristics for determining prognosis in these patients. As liver transplantation becomes a more accessible option for patients with acute liver failure, the King's College Criteria serve a role in determining which patients may require transplantation.
Clinical pharmacy is the branch of pharmacy in which clinical pharmacists provide direct patient care that optimizes the use of medication and promotes health, wellness, and disease prevention. Clinical pharmacists care for patients in all health care settings but the clinical pharmacy movement initially began inside hospitals and clinics. Clinical pharmacists often work in collaboration with physicians, physician assistants, nurse practitioners, and other healthcare professionals. Clinical pharmacists can enter into a formal collaborative practice agreement with another healthcare provider, generally one or more physicians, that allows pharmacists to prescribe medications and order laboratory tests.
The American Society of Transplantation (AST) is an international organization of over 4,000 transplant professionals dedicated to advancing the field of transplantation through the promotion of research, education, advocacy, organ donation, and service to the community through a lens of equity and inclusion. It is the largest professional transplantation society in North America.
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is the impaired liver function caused by the formation of scar tissue known as fibrosis due to damage caused by liver disease. Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. Over time, scar tissue can replace normal functioning tissue, leading to the impaired liver function of cirrhosis. The disease typically develops slowly over months or years. Early symptoms may include tiredness, weakness, loss of appetite, unexplained weight loss, nausea and vomiting, and discomfort in the right upper quadrant of the abdomen. As the disease worsens, symptoms may include itchiness, swelling in the lower legs, fluid build-up in the abdomen, jaundice, bruising easily, and the development of spider-like blood vessels in the skin. The fluid build-up in the abdomen may develop into spontaneous infections. More serious complications include hepatic encephalopathy, bleeding from dilated veins in the esophagus, stomach, or intestines, and liver cancer.
The American Society for Apheresis (ASFA) is an organization of physicians, scientists, nurses, and allied health professionals whose mission is to advance apheresis medicine for patients, donors and practitioners through education, evidence-based practice, research and advocacy. ASFA represents a broad range of health care professionals involved in apheresis medicine including those practicing pathology, transplantation, hematology, oncology, neurology, rheumatology, nephrology, hepatology, gastroenterology, cardiology, and ophthalmology. These health care providers are involved in the performance of therapeutic apheresis procedures including plasma exchange, red cell exchange, leukocytapheresis, plateletapheresis, photopheresis, LDL apheresis, and hematopoietic progenitor cell collection. ASFA also represents those physicians and allied health professionals involved in the collection of blood products from blood donors using apheresis instruments.
The European Association for the Study of the Liver (EASL) is a European professional association for those researching liver disease.
Andrew K. Burroughs was a British physician, researcher and teacher. He is renowned for his wide contribution to the field of Hepatology; he has been termed one of the greatest hepatologists of our times and the true representative of Dame Sheila Sherlock's legacy.
Anna Suk-Fong Lok is a gastroenterologist who studied in Hong Kong and moved to the United States in 1992. She is a Professor of Medicine at the University of Michigan in Ann Arbor and helped the World Health Organization (WHO) and American Association for the Study of Liver Diseases (AASLD) develop guidelines for medical professionals and recommendations for the general public on who should be treated and how treatments should be administered to persons with hepatitis B infections.
Mamun Al Mahtab is a Bangladeshi hepatologist, medical scientist, author, and columnist. With 290 publications in national and international peer-reviewed journals to his credit, Mahtab is currently working as the Head, Division of Interventional Hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU). In 1998, he graduated from the University of London with an MSc in gastroenterology, and then in 2006, he obtained an MD in hepatology at Bangabandhu Sheikh Mujib Medical University(BSMMU).
References
- ↑ "AASLD CME/CEU Activities". Events and Professional Development. AASLD. July 19, 2016. Archived from the original on April 23, 2019. Retrieved May 16, 2019.
- ↑ Reau, Nancy (July 19, 2016). "Clinical Liver Disease, a multimedia review journal". Clinical Liver Disease . Wiley.com. doi:10.1002/(ISSN)2046-2484. ISSN 2046-2484.
